Pharma

Your Article Summary

See Latest Articles

Abbott Launches Next-Generation XIENCE PRIME Drug Eluting Stent in International Markets
Abbott, 09/01/09

Abbott announced at the European Society of Cardiology Congress the widespread availability of its next–generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which received CE Mark in June, offers a novel stent design and a delivery system designed for greater flexibility and enhanced deliverability. XIENCE PRIME is now widely available in Europe and in select countries throughout Asia–Pacific and Latin America.

Today in Marketing/Media/ROI...keeping you current

Receive free subspecialty "5-minute updates" via email

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09

Shire Reports Tolerability and Clinical Effects Results of DAYTRANA from Study in Adolescents with ADHD
Shire, 11/02/09

See All of Marketing/Media/ROI

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09

FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 10/30/09

Gyrus PlasmaKinetic bipolar coagulation device for liver resection
Australian and New Zealand Journal of Surgery, 11/13/09

See All of Medical Devices/Products